viewMedlab Clinical Ltd

Medlab Clinical does deal for global distribution of NanaBis

The development and distribution deal is in the form of a heads of agreement.

collaboration concept
The HoA is with Canada’s fourth largest generic pharmaceutical company

Medlab Clinical Ltd (ASX:MDC) has entered an agreement with Canadian pharmaceutical company, Pharmascience Inc. for the further development and global distribution of NanaBis.

The terms of the HoA provide for both parties to negotiate various research, regulatory and commercial milestones involving potential global territories for NanaBis.

READ: Medlab Clinical takes EMA and FDA approval track as cannabis research continues

NanaBis is a highly purified proprietary blend of cannabis molecules cannabidiol (CBD) and tetrahydrocannabinol (THC).

It is delivered into the body using Medlab’s patented sub-micron delivery platform NanoCelle.

NanaBis is a buccal (side of cheek) spray currently in the second stage of an Australian advanced cancer pain trial.

Patients can access it under the government’s Special Access Scheme and it is currently before several regulatory agencies for potential fast track drug approval pathways.

Medlab’s CEO Dr Sean Hall said: “NanaBis is in an exciting stage of its development as the company looks to fast track global drug approval pathways.

This Heads of Agreement signifies real intent and interest for a true global pharmaceutical company to enter legitimate science as it relates to cannabis that has been research focused into a serious condition: cancer pain.

Collaborating with global companies allows faster expansion

Dr Hall added: “being able to collaborate with global pharmaceutical companies like Pharmascience Inc. allows MDC the opportunity to expand NanaBis quicker in global territories including USA and Canada”.

Quick facts: Medlab Clinical Ltd

Price: 0.2 AUD

Market: ASX
Market Cap: $55.94 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...


Medlab Clinical forges ahead in new vitamin trials for chronic illnesses

Medlab Clinical Ltd (ASX:MDC) chief executive officer Sean Hall tells Proactive Investors how the company is tapping into new areas of its “therapeutic toolkit” to better assist those with chronic health conditions.   Hall says there has been a shortfall in the standard of...

on 05/07/2019

2 min read